Wesana Health
Pioneering drug development and clinical therapies utilizing psychedelic medicine for mental health care.
Pioneering drug development and clinical therapies utilizing psychedelic medicine for mental health care.
Wesana Health is an innovative player in the healthcare industry, founded in 2020. The company is focused on pioneering drug development and clinical therapies utilizing psychedelic medicine for mental health care. With its headquarters in the United States, Wesana has been making waves with its groundbreaking approach. As of 31 March 2021, the company received a notable $16.10MPost-IPO equity investment, a testament to its potential and investor interest. The investors, including K2 & Associates, Negev Capital, SOL Global Investments, JLS Fund, Ambria Capital, LLC, George Steinbrenner, and Gravitas Securities, demonstrate the confidence and backing Wesana has garnered within the investment community. Wesana Health's commitment to advancing psychedelic medicine in mental health positions it as a promising venture, offering potential for significant growth and impact in the healthcare sector.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $16.10M | 7 |
|
31 Mar 2021 |
| Convertible Note | $4.00M | 3 |
|
21 Jan 2021 |
No recent news or press coverage available for Wesana Health.
We care about your data, and we'd love to use cookies make your experience better.
